Innate Lymphoid Cells - Neglected Players in Multiple Sclerosis

Hassanabadi, Negar Sadeghi; Broux, Bieke; Marinović, Sonja; Gotthardt, Dagmar

doi:10.3389/fimmu.2022.909275

Cited by 11 publications

(7 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-2 production was impaired in PwMS independently of the booster dose, whereas HCWs showed an IL-2 specific T-cell response. IL-2 is involved in the cell activation associated with a worsening of the MS disease status33; therefore, the IL-2 production impairment may indirectly explain the lack of MS worsening symptoms after SARS-CoV-2 vaccination. Interestingly, an impaired IL-2 production was also found in COVID-19 vaccinated patients with other autoimmune diseases, including rheumatoid arthritis 34…”

Section: Discussionmentioning

confidence: 99%

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies

Aiello

Coppola

Ruggieri

et al. 2022

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

BackgroundThe decline of humoral response to COVID-19 vaccine led to authorise a booster dose. Here, we characterised the kinetics of B-cell and T-cell immune responses in patients with multiple sclerosis (PwMS) after the booster dose.MethodsWe enrolled 22 PwMS and 40 healthcare workers (HCWs) after 4–6 weeks from the booster dose (T3). Thirty HCWs and 19 PwMS were also recruited 6 months (T2) after the first dose. Antibody response was measured by anti-receptor-binding domain (RBD)-IgG detection, cell-mediated response by an interferon (IFN)-γ release assay (IGRA), Th1 cytokines and T-cell memory profile by flow cytometry.ResultsBooster dose increased anti-RBD-IgG titers in fingolimod-treated, cladribine-treated and IFN-β-treated patients, but not in ocrelizumab-treated patients, although antibody titres were lower than HCWs. A higher number of fingolimod-treated patients seroconverted at T3. Differently, T-cell response evaluated by IGRA remained stable in PwMS independently of therapy. Spike-specific Th1-cytokine response was mainly CD4+T-cell-mediated, and in PwMS was significantly reduced (p<0.0001) with impaired IL-2 production compared with HCWs at T3. In PwMS, total Th1 and IFN-γ CD4+T-cell responders to spike protein were increased from T2 to T3.Compared with HCWs, PwMS presented a higher frequency of CD4+and CD8+terminally differentiated effector memory cells and of CD4+effector memory (TEM) cells, independently of the stimulus suggesting the association of this phenotype with MS status. CD4+and CD8+TEMcell frequency was further increased at T3 compared with T2.ConclusionsCOVID-19 vaccine booster strengthens humoral and Th1-cell responses and increases TEMcells in PwMS.

show abstract

Section: Discussionmentioning

confidence: 99%

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies

Aiello

Coppola

Ruggieri

et al. 2022

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

show abstract

“…Multiple sclerosis (MS) is a well-known autoimmune disease that affects the central nervous system. Numerous studies have demonstrated the significant involvement of ILCs in both the onset and progression of this disease ( 35 , 36 ). The interaction between the nervous system and immune cells, such as ILCs, is complex and not fully understood ( 37 ).…”

Section: Discussionmentioning

confidence: 99%

Global research trends on innate lymphoid cells in the brain, gut and lung field: a bibliometric and visualized analysis

Huang,

Deng,

Liu

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundILCs play important roles in the brain, gut, and lungs. Researchers are attempting to establish a research framework on the brain-gut-lung axis using ILCs. However, no one has yet conducted a bibliometric analysis to summarize the findings. In this study, we utilized bibliometrics to analyze the emerging trends and focal areas of ILCs in the brain, intestine, and lung. We aim to provide references for future research on the brain-gut-lung axis.MethodsTo conduct a comprehensive bibliometric analysis on ILCs in the fields of brain, intestine, and lung, we utilized software such as HistCite, VOSviewer, and CiteSpace. Our analysis focused on various aspects, including the number of publications, countries, authors, journals, co-cited documents, and keywords. This approach allowed us to gain valuable insights into the research landscape surrounding ILCs in these specific fields.ResultsA total of 8411 articles or reviews on ILCs in the fields of brain, intestine, and lung were included. The number of published articles has shown a consistent upward trend since 2003. A total of 45279 authors from 99 countries have contributed to these articles. The United States has the highest number of publications (n=3044) and the most cited articles (TGCS=210776). The top three published authors in this field are David Artis, Marco Colonna and Andrew NJ McKenzie. The journal Immunity is the most authoritative choice for researchers. The main research focuses in this field include NK cell, ILC2, tumor immunity, multiple sclerosis, inflammatory bowel disease, airway inflammation, RORγT, and immunotherapy. In recent years, cancer and tumor microenvironment have emerged as hot keywords, particularly immunotherapy, PD-1 related directions, indicating a potential shift in research focus.ConclusionEuropean and American countries have been pivotal in conducting research on ILCs, while China has produced a significant number of publications, its impact is still limited. Tumors are likely to emerge as the next focal points in this field. The connection and regulation between the brain and the lung are not yet fully understood, and further investigation is necessary to explore the role of ILCs in the brain-lung axis.

show abstract

“…The involvement of ILCs has been demonstrated in the pathogenesis of multiple sclerosis (MS), mostly by using experimental autoimmune encephalomyelitis (EAE), a model of MS ( Sadeghi Hassanabadi et al, 2022 ). EAE is induced in mice by active immunization with myelin antigens mixed with adjuvant ( Miller et al, 2010 ).…”

Section: Ilcs In Autoimmune Neuroinflammation Neurodegenerative Disea...mentioning

confidence: 99%

Innate lymphoid cells in neuroinflammation

Kveštak,

Mihalić,

Jonjić

et al. 2024

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Innate lymphoid cells (ILCs) are largely tissue-resident cells that participate in the maintenance of tissue homeostasis and react early to inflammatory events. Mature ILCs are divided into three major groups based on the transcription factors required for their development and function. Under physiological conditions, ILCs are present within the choroid plexus and meninges while the CNS parenchyma is almost devoid of these cells. However, pathological conditions such as autoimmune neuroinflammation and viral infections of the CNS result in the infiltration of ILCs into parenchyma. In this article, we provide an overview of the involvement and function of the ILCs within the CNS during physiological conditions and in infections, autoimmune diseases, neurodegeneration, and injury.

show abstract

Innate Lymphoid Cells - Neglected Players in Multiple Sclerosis

Cited by 11 publications

References 65 publications

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies

Global research trends on innate lymphoid cells in the brain, gut and lung field: a bibliometric and visualized analysis

Innate lymphoid cells in neuroinflammation

Contact Info

Product

Resources

About